According to Fast Company, “An FDA decision summary released today allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that leads to a predisposition in carriers toward the development of cancer. While, on...
In a press release from FDA.gov, “The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with...
The 7th Semi-Annual Medical Device and Diagnostic Sales Training and Development Conference was held September 21-22, 2015 in San Diego, California.[View the story “Highlights from the 7th Semi-Annual Medical Device and Diagnostic Sales Training and Development...
J. Andy Newsom Vice President and Chief Information Officer CSL Behring Andy will be one of the distinguished speakers at the Life Science Tech Summit. Why is the Life Science Tech Summit important for IT executives? The summit is an opportunity for Life...
According to MassDevice.com, on September 21, 2015, “NovoCure set the terms on its forthcoming initial public offering, saying it expects to float 7.5 million shares at $26 to $29 apiece, or $206.3 million at the midpoint of the range. NovoCure said it expects...
